Clinical Trials Logo
  1. Home
  2. Immune Thrombocytopenic Purpura
  3. NCT03363334
  4. Details
NCT03363334 Clinical Trial

Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

Immune Thrombocytopenic Purpura Clinical Trial

Official title:
Expanded Access (Compassionate Use) of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory Immune Thrombocytopenic Purpura (ITP)

Clinical Trial Details — Status: No longer available

Administrative data
NCT number NCT03363334
Other study ID # C-935788-055
Secondary ID
Status No longer available
Phase
First received
Last updated

Study information
Verified date June 2018
Source Rigel Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

C-935788-055 is an open-label, multi-center, expanded access (EAP) study.

Description:

The purpose of the program is to provide Fostamatinib in an Expanded Access setting to subjects who meet the selection criteria.

Recruitment information / eligibility
Status No longer available
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Adult patient with chronic or persistent ITP.

2. Must have failed or are unable to receive standard of care treatments for ITP.

3. Must have at least two platelet counts < 30,000/µL during the last 2 months prior to screen date.

Exclusion Criteria:

1. ITP associated with lymphoma, chronic lymphocytic leukemia, transplant, or thrombocytopenia associated with myeloid dysplasia.

2. Subject has uncontrolled or poorly controlled hypertension.

3. Any of the following laboratory abnormalities: neutrophil count of < 1,500/µL, or transaminase levels (ALT, AST) > 1.5x ULN, total bilirubin > 2.0 mg/dL.

4. Active HBV or HCV infection.

5. Current or recent enrollment in an investigational drug or device study.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Fostamatinib disodium 100 mg
Fostamatinib Disodium tablet 100 mg PO bid (morning and evening)
• Fostamatinib disodium 150 mg
Fostamatinib Disodium tablet 150 mg PO bid (morning and evening)

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Rigel Pharmaceuticals
See also
  Status Clinical Trial Phase
Recruiting NCT01255332 - Helicobacter Pylori Immune Thrombocytopenic Purpura Phase 2
Completed NCT02077192 - Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT01621204 - A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients Phase 3
Completed NCT01719692 - Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia N/A
Completed NCT01730352 - Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients Phase 2/Phase 3
Completed NCT01713855 - Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura N/A
Not yet recruiting NCT05093257 - Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura
Completed NCT01390649 - A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Phase 4
Completed NCT01672151 - Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia N/A
Completed NCT01439321 - Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim N/A
Completed NCT00774202 - Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP Phase 2/Phase 3
Completed NCT02273960 - Study to Evaluate Safety and Efficacy in Adult Subjects With ITP Phase 1/Phase 2
Not yet recruiting NCT05585944 - " Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura " N/A
Recruiting NCT03177629 - H. Pylori Eradication for Moderate ITP Phase 3
Not yet recruiting NCT05835050 - Assessment of Serum interleukin10 Level in Patients With Immune Thrombocytopenic Purpura at Sohag University Hospital N/A
Active, not recruiting NCT03395210 - A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP) Phase 2
Completed NCT00621894 - Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation Phase 2
Completed NCT01652599 - Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT Phase 2
Completed NCT00426270 - Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults Phase 3
Completed NCT02085993 - Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training N/A